What is Customer Demographics and Target Market of STAAR Surgical Company?

Who are STAAR Surgical's customers?

Understanding customer demographics and target markets is paramount for STAAR Surgical Company's strategic success. A pivotal moment was the growing acceptance of implantable collamer lenses (ICLs) as a premium vision correction solution, impacting those seeking alternatives to traditional laser eye surgery or glasses.

STAAR Surgical Company, founded in 1982, has evolved into a specialized leader in phakic IOLs, with approximately 100% of its net sales in fiscal year 2024 coming from ICLs. This highlights a strategic shift towards serving individuals seeking visual freedom from glasses and contact lenses, moving away from its earlier focus on cataract surgery products.

What is Customer Demographics and Target Market of STAAR Surgical Company?

STAAR Surgical's primary target market consists of individuals aged 21-45 who are seeking a premium vision correction solution. These individuals are typically active, health-conscious, and have disposable income, valuing convenience and a high quality of life. They are often dissatisfied with their dependence on glasses or contact lenses and are looking for a long-term, effective alternative. This demographic often includes professionals, athletes, and those in careers where clear vision without corrective eyewear is advantageous. The company's flagship product, the Visian ICL, is positioned as a sophisticated solution for this discerning group, offering visual clarity and freedom. The STAAR Surgical BCG Matrix analysis would further detail the strategic positioning of their offerings within this market. In 2024, the company continued to see strong demand from this segment globally.

STAAR Surgical's primary customer segments are ophthalmic surgeons and clinics who purchase their implantable lenses. However, the ultimate beneficiaries are individuals seeking advanced vision correction, particularly those with moderate to high myopia, hyperopia, and astigmatism who may not be suitable for laser procedures.

Primary Patient Profile for ICLs

The core STAAR Surgical patient demographics for ICLs typically include adults with significant refractive errors. These individuals often have thin corneas or high prescriptions that make laser vision correction less ideal.

Market Size and Growth Potential

The global refractive surgery market is expanding, driven by increasing rates of myopia. In the US alone, approximately 13 million people, or 4% of the population, have myopia.

Target Market Income and Age Considerations

While specific income and education data for patients are not always public, refractive surgery, including ICLs, is often an elective, out-of-pocket expense. This suggests a target market with disposable income.

STAAR Surgical's Strategic Focus

STAAR Surgical's sales are overwhelmingly driven by ICLs, accounting for approximately 100% of total sales in fiscal 2024. This highlights a dedicated focus on the refractive lens market.

Expanding the Addressable Market

STAAR Surgical is actively broadening its STAAR Surgical target market with innovations like the EVO Viva lens for presbyopia. This expansion aims to capture a larger segment of the vision correction market.

• Immediate target market estimated at 5.2 million surgical procedures in 2025.
• Broader potential market includes 2.7 billion people with myopia.
• Focus on the 21-45 age range for primary vision correction needs.
• The company has shifted away from cataract IOLs to concentrate on refractive lens exchange.

STAAR Surgical's customer base primarily consists of individuals seeking advanced vision correction solutions, often those who are not ideal candidates for laser refractive surgery. These patients are driven by a desire for enhanced visual acuity and an improved quality of life, valuing safety and the reversible nature of implantable collamer lenses (ICLs).

Visual Freedom

A core need for ICL patients is the freedom from glasses and contact lenses. This desire is amplified by modern lifestyles, including increased screen time and associated digital eye strain.

High-Quality Vision

Patients prioritize excellent visual outcomes, seeking sharp and clear vision across various lighting conditions. The EVO ICL is marketed to deliver this superior visual performance.

Safety and Reversibility

The safety profile and the ability to reverse the procedure are significant factors. Patients are reassured by the lens's biocompatibility and the option for removal if needed.

Convenience and Lifestyle

Beyond vision correction, patients seek convenience and the ability to engage in an active lifestyle without the encumbrance of corrective eyewear.

Addressing Discomfort

Many ICL candidates experience discomfort, dryness, or inconvenience with glasses and contact lenses, making ICLs an attractive alternative.

Long-Term Value

The long-term cost-effectiveness compared to the continuous expenses of glasses and contact lenses is a practical consideration for many patients.

STAAR Surgical actively addresses these patient needs through ongoing product innovation and targeted marketing strategies. The company highlights the extensive clinical evidence supporting the safety and efficacy of its ICL technology, citing hundreds of peer-reviewed articles. Market trends, such as the increasing global prevalence of myopia, inform product development, exemplified by the introduction of the EVO Viva lens for presbyopia. This strategic approach aims to provide solutions for a broader range of refractive errors, including myopia, hyperopia, and astigmatism. The company also focuses on empowering ophthalmic professionals through comprehensive training programs, including wet labs and proctorships. In 2024, over 1,200 healthcare professionals globally received EVO ICL training and certification, underscoring STAAR Surgical's commitment to supporting its B2B partners in delivering advanced vision correction to patients. Understanding the Target Market of STAAR Surgical is crucial for appreciating these efforts.

Addressing Evolving Needs

STAAR Surgical's product development is influenced by evolving patient needs and market dynamics, such as the growing demand for solutions addressing presbyopia.

• Development of lenses like EVO Viva for presbyopia addresses the need for reading independence.
• The company's focus on myopia correction aligns with the increasing global prevalence of this condition.
• Emphasis on clinical data and peer-reviewed articles builds trust and addresses patient preference for proven safety.
• Tailored professional education programs ensure that eye care professionals can effectively offer ICL solutions.

STAAR Surgical Company has established a broad international footprint, distributing its products in over 75 countries. In the fiscal year ending December 27, 2024, a significant majority, approximately 94%, of its global revenue originated from sales outside the United States, underscoring its extensive international market penetration.

Global Reach

STAAR Surgical operates in more than 75 countries, with the vast majority of its revenue, around 94% in fiscal year 2024, coming from international markets.

Key Market Presence

The company has direct distribution in major markets like Japan and Germany, and maintains a European headquarters in Switzerland, alongside commercial offices in China, India, Singapore, and the U.K.

China Market Dynamics

China was historically the largest market, contributing $161.0 million in ICL sales in fiscal year 2024. However, recent economic factors led to a substantial revenue decline in Q1 2025, with sales dropping to $389,000 from $38.5 million in the prior year quarter.

Growth Outside China

Excluding China, ICL sales grew by 13% in fiscal year 2024 to $151.6 million, with Q4 2024 seeing a 17% increase. The Americas region showed particularly strong growth, with a 19% increase in ICL sales for the fiscal year.

STAAR Surgical focuses on localizing its strategies and invests heavily in surgeon education globally, recognizing the importance of these efforts for market share capture, as seen in Japan, China, and South Korea. The company trained over 1,200 healthcare professionals in EVO ICL procedures in 2024, reinforcing its commitment to expanding the STAAR Surgical patient profile and refractive surgery market.

Regional Performance

While China experienced a downturn, markets outside China demonstrated robust growth, with the Americas region leading in Q4 2024. The company anticipates sustained double-digit growth globally, excluding China, throughout 2025.

Market Share Strategy

Success in markets like Japan, China, and South Korea informs the company's approach to other regions. This strategy aims to capture significant market share by understanding and adapting to local needs.

Surgeon Education

Global investment in surgeon training is a cornerstone of the company's market expansion. This includes the establishment of advanced training centers to ensure widespread adoption of its technologies.

Product Focus

The company's primary focus is on its implantable lenses, catering to a diverse STAAR Surgical patient profile seeking vision correction alternatives to LASIK and PRK.

Geographical Segmentation

STAAR Surgical's market segmentation strategy leverages its presence in key geographical areas to drive growth in the vision correction market.

Revenue Diversification

The company's international sales, detailed in Revenue Streams & Business Model of STAAR Surgical, highlight its strategy for revenue diversification across various global markets.

STAAR Surgical employs a dual-pronged approach to customer acquisition and retention, primarily targeting ophthalmic surgeons and clinics while simultaneously cultivating patient demand. This strategy is reinforced by strategic partnerships and ongoing professional education to ensure widespread adoption and proficiency with their implantable lenses.

Surgeon Acquisition Through Partnerships

STAAR Surgical focuses on acquiring new surgeons and clinics through strategic collaborations. An example is their May 2024 agreement with IQ Laser Vision, aiming to significantly increase EVO ICL usage. These partnerships involve joint marketing, education, and clinical support to boost awareness and accessibility.

Professional Education for Adoption

The company utilizes digital platforms, traditional advertising, and extensive professional education to reach its target market. STAAR University, launched in 2024, provides surgeons with vital resources like clinical data to enhance their confidence and skills with ICL procedures.

Patient Demand Generation

While the primary focus is B2B, STAAR Surgical also works to build direct patient demand for its vision correction solutions. This indirect approach ensures that when surgeons are proficient, there is a patient base seeking these advanced treatments.

Retention via Innovation and Support

Retention is driven by continuous product innovation, such as the EVO Viva lens for presbyopia, and a commitment to high-quality, safe products with over 3,000,000 ICLs sold globally. Ongoing support for surgeons ensures they remain confident and continue to offer STAAR's lenses.

The company's strategic shift towards focusing on refractive lenses, particularly the EVO ICL line, has streamlined its marketing and sales efforts. Efforts to accelerate growth in 'EVO-ready practices' suggest a data-driven approach to segmentation. Despite recent challenges, STAAR Surgical is investing in commercial operations and innovation, with plans to optimize its SG&A run rate to approximately $225 million by the end of 2025, anticipating a return to profitability in the latter half of the year.

Targeting Refractive Surgery Market

STAAR Surgical's strategy is heavily geared towards the refractive surgery market, emphasizing products like the EVO ICL. This focus allows for specialized marketing and education tailored to surgeons and patients seeking vision correction alternatives to LASIK or PRK.

Surgeon Training as Retention Driver

By providing comprehensive training and ongoing support through programs like STAAR University and proctorships, the company ensures surgeon satisfaction. This indirectly fosters patient retention, as proficient and satisfied surgeons are more likely to continue recommending and using the company's implantable lenses.

Product Innovation for Broad Appeal

Introducing innovative products that address a wider range of patient needs, such as the EVO Viva lens for presbyopia, is a key retention strategy. This expands the potential patient pool for their surgeon partners, thereby increasing the long-term value proposition.

Data-Driven Practice Acceleration

The company utilizes customer data to identify and accelerate growth in 'EVO-ready practices'. This segmentation allows for more targeted support and resource allocation, enhancing the effectiveness of their acquisition and retention efforts.

Financial Optimization for Growth

STAAR Surgical is actively managing its operational costs, aiming to optimize its SG&A run rate to approximately $225 million by the end of 2025. This financial discipline supports continued investment in commercial operations and innovation, crucial for long-term growth and profitability.

Focus on Premium Vision Correction

The company's strategic direction clearly indicates a commitment to the premium vision correction market. By phasing out cataract IOLs to concentrate on refractive surgery, STAAR Surgical aims to capture a larger share of this high-value segment, aligning with the Mission, Vision & Core Values of STAAR Surgical.